Neurogene Inc (NGNE) - Total Liabilities

Latest as of March 2026: $25.36 Million USD

Based on the latest financial reports, Neurogene Inc (NGNE) has total liabilities worth $25.36 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Neurogene Inc annual equity growth to track the company's year-over-year net asset growth rate.

Neurogene Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Neurogene Inc's total liabilities have evolved over time, based on quarterly financial data. See Neurogene Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Neurogene Inc Competitors by Total Liabilities

The table below lists competitors of Neurogene Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Henan Ancai Hi-tech Co Ltd SHG:600207	China	CN¥4.02 Billion
Mengtian Home Group Inc. SHG:603216	China	CN¥388.60 Million
JINXIN FERT.GRP HD-00001 F:3NX	Germany	€4.76 Billion
Guangdong Mingzhu Group Co Ltd SHG:600382	China	CN¥580.64 Million
Oculis Holding AG Ordinary shares NASDAQ:OCS	USA	$39.94 Million
Yabao Pharmaceutical Group Co Ltd SHG:600351	China	CN¥585.77 Million
Jana Small Finance Bank NSE:JSFB	India	Rs429.78 Billion
Shenzhen Absen Optoelectronic Co Ltd SHE:300389	China	CN¥2.64 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Neurogene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Neurogene Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	13.08	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.10	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Neurogene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Neurogene Inc (2011–2025)

The table below shows the annual total liabilities of Neurogene Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	$23.72 Million	-6.46%
2024-12-31	$25.36 Million	-30.63%
2023-12-31	$36.55 Million	+243.57%
2022-12-31	$10.64 Million	-94.50%
2021-12-31	$193.36 Million	+901.72%
2020-12-31	$19.30 Million	+261.75%
2019-12-31	$5.34 Million	+7.89%
2018-12-31	$4.95 Million	-56.77%
2017-12-31	$11.44 Million	+17.76%
2016-12-31	$9.72 Million	+97.36%
2015-12-31	$4.92 Million	-6.68%
2014-12-31	$5.28 Million	-29.51%
2013-12-31	$7.48 Million	+409.83%
2012-12-31	$1.47 Million	+13.13%
2011-12-31	$1.30 Million	--

About Neurogene Inc

NASDAQ:NGNE USA Biotechnology

Market Cap

$656.17 Million

Market Cap Rank

#10702 Global

#2818 in USA

Share Price

$32.89

Change (1 day)

-2.11%

52-Week Range

$16.37 - $42.84

All Time High

$395.20